Regen BioPharma Peer-Reviewed Publication Provides Preclinical Support for HemaXellerate(TM) Bone Marrow Failure Product
24 January 2013 - 7:53PM
Marketwired
Regen BioPharma, a wholly owned subsidiary of Bio-Matrix Scientific
Group Inc. (PINKSHEETS: BMSN), announced today publication in a
peer reviewed medical journal the scientific basis for its
HemaXellerate™ bone marrow failure product. The manuscript is
available at
http://www.translational-medicine.com/content/pdf/1479-5876-10-231.pdf.
The publication is an overview of the Investigational New Drug
(IND) application that the company plans to file for initiating
clinical trials.
HemaXellerate™ is a cell therapy product developed by Regen
BioPharma that uses fat derived from the patient as a source of
"healing cells" to stimulate bone marrow production of blood cells.
These "healing cells" are termed "endothelial cells" and are a
critical component of the blood production machinery of the bone
marrow that is damaged in patients with bone marrow failure.
Intellectual property covering the HemaXellerate™ product
include US Provisional Patent applications 61/648898 - Acceleration
of Hematopoietic Reconstitution by Placental Endothelial and
Endothelial Progenitor Cells and 61/670791 - Treatment of
Hematopoietic Disorders filed by Regen, as well as an option to
exclusively license issued US Patent #6,821,513.
Currently, the only way to stimulate production of blood from
bone marrow is through administration of growth factors. The
overall market for growth factors is $18 billion per year.
Unfortunately, growth factors require repeated administration, are
expensive, and in many patients are ineffective.
"Treatments available today for patients with insufficient bone
marrow function are a 'band-aid' solution that require repeated
administration and do not address the underlying cause of bone
marrow failure," said David Koos, Chairman and CEO of Bio-Matrix,
and a co-author of the publication. "We believe that HemaXellerate™
offers the possibility to actually heal damage that has occurred to
the bone marrow and thus more naturally treat the core of cause of
bone marrow inactivity."
The publication contained data obtained from independent
laboratories supporting the use of HemaXellerate™ as an alternative
to growth factor therapy and was a co-authored by stem cell
pioneers Dr. Amit Patel from University of Utah, and Dr. Michael
Murphy from Indiana University. Additionally, the paper was
co-authored by companies working in the field of stem cells
including Cook Biotechnology and Medistem, Inc.
Regen BioPharma's first indication of HemaXellerate™ will be
patients with aplastic anemia who are drug resistant and not
eligible for bone marrow transplantation. Demonstration of efficacy
in this patient population is anticipated to lead the way for entry
into the $18 billion hematopoietic growth factor market which
includes conditions such as anemia, thrombocytopenia, and
chemotherapy associated leukopenia.
About Bio-Matrix Scientific Group Inc. and Regen BioPharma,
Inc.:
Bio-Matrix Scientific Group, Inc. (PINKSHEETS: BMSN) is a
biotechnology company developing regenerative medicine therapies.
The Company is focused on human therapies that address unmet
medical needs. Specifically, Bio-Matrix Scientific Group Inc. is
looking to increase the quality of life through therapies involving
stem cell treatments. These treatments are focused in areas
relating to cardiovascular, hematology, oncology and other
indications.
Regen BioPharma, Inc., a subsidiary of Bio-Matrix Scientific
Group, Inc. (PINKSHEETS: BMSN), is a biotechnology company focused
on identifying undervalued regenerative medicine patents in the
stem cell space and rapidly advancing these technologies through
pre-clinical and Phase I/ II clinical trials. To follow our
development, visit us at www.regenbiopharma.com.
Disclaimer
This news release may contain forward-looking statements.
Forward-looking statements are inherently subject to risks and
uncertainties, some of which cannot be predicted or quantified.
Future events and actual results could differ materially from those
set forth in, contemplated by, or underlying the forward-looking
statements. The risks and uncertainties to which forward looking
statements are subject include, but are not limited to, the effect
of government regulation, competition and other material risks
Contact: Bio-Matrix Scientific Group, Inc. David R. Koos, PhD
Chairman & Chief Executive Officer 619-702-1404 www.bmsn.us
Email Contact